Research Article
Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors
| Variable | Number of patients | % |
| Patient number | 110 | 100 | Gender | | | Male | 100 | 90.9 | Female | 10 | 9.1 | Age (year) median (range) | 54.5 (31-84) | | ECOG performance score | | | 0-1 | 78 | 70.9 | ≥2 | 32 | 29.1 | Child-Pugh class | | | A | 98 | 89.1 | B | 12 | 10.9 | BMI | | | <25 | 80 | 72.7 | ≥25 | 30 | 27.3 | Viral hepatitis | | | HBV | 110 | 100 | BCLC stage | | | B | 18 | 16.4 | C | 92 | 83.6 | CNLC stage | | | IIb | 18 | 16.4 | IIIa | 23 | 20.9 | IIIb | 69 | 62.7 | Treatment of primary tumor | | | TACE | 87 | 79.1 | RFA | 15 | 13.6 | RT | 25 | 22,7 | Resection of liver cancer | 33 | 30 | None | 15 | 13.6 | The cycles of anti-PD-1 therapy | | | Two cycles | 55 | 50.0 | More than three cycles | 55 | 50.0 | PVTT | | | Yes | 65 | 59.1 | None | 45 | 40.9 | AFP level | | | <400 ng/ml | 49 | 44.5 | ≥400 ng/ml | 61 | 55.5 | Lymphocyte 10^9/LMedian (range) | 1.233 (0.18-4.09) | | Neutrophil 10^9/L median (range) | 3.339 (0.97-10.53) | | Monocyte 10^9/L median (range) | 0.46 (0.13-1.38) | | Platelet 10^9/L median (range) | 141.67 (27-496) | | SII | | | <970 | 99 | 90.0 | ≥970 | 11 | 10.0 | PLR | | | <140 | 69 | 62.7 | ≥140 | 41 | 37.3 | NLR | | | <5 | 89 | 80.9 | ≥5 | 21 | 19.1 | LMR | | | <1.8 | 31 | 28.2 | ≥1.8 | 79 | 71.8 |
|
|